Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 6/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.64 |
| ▸ | MC5R | P33032 | 1/20 | 0.64 |
| ▸ | MC3R | P41968 | 1/20 | 0.64 |
| ▸ | MC1R | Q01726 | 1/20 | 0.64 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.63 |
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | CTSS | P25774 | 2/20 | 0.62 |
| ▸ | CTSK | P43235 | 2/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.62 |
| ▸ | GLP1R | P43220 | 5/20 | 0.61 |
| ▸ | CTSH | P09668 | 1/20 | 0.61 |
| ▸ | GCGR | P47871 | 3/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.59 |
| ▸ | NPY1R | P25929 | 1/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332244 | 1.00 | CXCL8 (0.64) | CXCL8MC4RMC5RMC3RMC1R | |
| SCHEMBL29462886 | 0.95 | MC4R (0.68) | CXCL8MC4RMC5RMC3RMC1R | |
| SCHEMBL29361885 | 0.95 | GLP1R (0.66) | CXCL8MC4RMC5RMC3RMC1R | |
| SCHEMBL30876339 | 0.91 | OPRD1 (0.58) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29874649 | 0.89 | MC4R (0.69) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29389654 | 0.88 | MC4R (0.67) | CXCL8MC4RMC5RMC3RMC1R | |
| SCHEMBL29581575 | 0.88 | MC4R (0.60) | CXCL8MC4RMC5RMC3RMC1R | |
| Dynorphin A (1-17) SCHEMBL31331988 | 0.87 | NPY1R (0.68) | C5AR1IL23RGLP1RCXCR4NPY1R | |
| Dynorphin A (1-17) SCHEMBL30248363 | 0.87 | NPY1R (0.68) | C5AR1IL23RGLP1RCXCR4NPY1R | |
| SCHEMBL31186277 | 0.87 | MC4R (0.61) | CXCL8MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114126615-B | Opioid receptor antagonist prodrugs | 尼萨姆实验室公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-3962510-B1 | NOVEL SELECTIVE ACKR3 MODULATORS AND USES THEREOF | LUXEMBOURG INST OF HEALTH LIH (LU) | 2024-08-28 | — | — | EP | disclosed |
| EP-3743422-B1 | CRYSTALLINE FORMS OF THE CXCR7 RECEPTOR ANTAGONIST (3S,4S)-1-CYCLOPROPYLMETHYL-4-{[5-(2,4-DIFLUORO-PHENYL)-ISOXAZOLE-3-CARBONYL]-AMINO}-PIPERIDINE-3-CARBOXYLIC ACID (1-PYRIMIDIN-2-YL-CYCLOPROPYL)-AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-13 | — | — | EP | disclosed |
| US-20240059688-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER | LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) | 2024-02-22 | — | — | US | disclosed |
| EP-4267579-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER AND CARDIOVASCULAR DISEASES | Luxembourg Institute of Health (LIH) (LU) | 2023-11-01 | — | — | EP | disclosed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110563717-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20220236279-A1 | Novel Selective ACKR3 Modulators and Uses Thereof | LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) | 2022-07-28 | — | — | US | disclosed |
| WO-2022136486-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER AND CARDIOVASCULAR DISEASES | LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) | 2022-06-30 | — | — | WO | disclosed |
| US-11339148-B2 | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-05-24 | — | — | US | disclosed |
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
| EP-3965765-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | Nirsum Laboratories, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126615-A | Opioid receptor antagonist prodrugs | 尼萨姆实验室公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | CXCL8 363/4885MC4R 600/4885MC5R 432/4885 |
| US-20240059688-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER | ACKR3, CMKLR1, CXCR4 | CXCL8 837/4885MC4R 293/4885MC5R 1201/4885 |
| US-11339148-B2 | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide | CXCR1, CXCR5, CXCR4 | CXCL8 123/4885MC4R 423/4885MC5R 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.